Latest research on Mometasone Furoate

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Latest findings

Locally, Mometasone Furoate monohydrate cream was applied twice daily. [source, 2006]
Objectives: To investigate patient satisfaction and efficacy of regular use of Nasonex in allergic rhinitis, with and without concomitant use of antihistamines. [source, 2005]
The patients were treated with Nasonex 50 mcg/spray two sprays in each nostril od for 14 days. [source, 2005]
Both simple and covariate analysis indicated a significant benefit of combination therapy of Nasonex with a non-sedating antihistamine compared to Nasonex alone. [source, 2005]
Also, daily use of Nasonex was significantly better than intermittent use. [source, 2005]
Conclusion: Patient symptom reduction and satisfaction are both very good for Nasonex. [source, 2005]
There was 1 study that assessed the dose-response of Budesonide, 7 of FP, 1 of BDP, 3 of Mometasone Furoate, and 2 of Triamcinolone Acetonide. [source, 2004]
Mometasone Furoate (MF) is a highly potent topical glucocorticoid for the treatment of asthma [1], allergic rhinitis [2] and various skin diseases [3]. [source, 2004]
Mometasone Furoate (MF), 6-hydroxy Mometasone Furoate (6-OH MF), mometasone and 9,11-epoxy Mometasone Furoate (9,11-epoxy MF) were generous gifts from GlaxoSmithKline (Greenford, England). [source, 2004]
In the present study we have determined the relative receptor binding affinities of the Mometasone Furoate (MF) metabolite 6β-OH MF and its degradation product 9,11-epoxy MF to understand their possible contribution to undesirable systemic side effects. [source, 2004]